Form 4: Verona Pharma CEO David Zaccardelli Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Verona Pharma's CEO, David Zaccardelli, executed sales of ordinary shares between October 23 and October 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- David Zaccardelli, the President and CEO of Verona Pharma plc, sold ordinary shares of the company between October 23 and October 25, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on March 8, 2024.
- On October 23, 2024, 16 ordinary shares were sold at a price of $4.375 each.
- On October 24, 2024, 140,000 ordinary shares were sold at a weighted average price of $4.3773.
- On October 25, 2024, 4,800 ordinary shares were sold at a weighted average price of $4.3758.
- Following these transactions, Zaccardelli directly owns 14,591,736 ordinary shares.
- These holdings include 2,825,000 ordinary shares underlying Restricted Share Units and 11,766,736 ordinary shares underlying American Depositary Shares (ADSs).
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock sales by an executive. It is neutral in tone and doesn't inherently indicate positive or negative sentiment.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, regardless of the reason for the sale.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without being accused of trading on non-public information.
Stakeholder Impact
- Shareholders may be interested in executive stock transactions as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-03-08 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-10-23 | Date of first transaction reported |
| 2024-10-24 | Date of second transaction reported |
| 2024-10-25 | Date of third transaction reported |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.